# Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease

> **NCT02158052** · NA · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 2 (actual)

## Conditions studied

- Multiple Myeloma
- Amyloidosis

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** Equine Anti-thymocyte globulin
- **PROCEDURE:** Kidney transplant from a related donor
- **DRUG:** Bone marrow transplant from a related donor
- **RADIATION:** Total body irradiation 400 centigray (200 cGy X 2)

## Key facts

- **NCT ID:** NCT02158052
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2021-06-22
- **Final completion:** 2021-06-22
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2022-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02158052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02158052, "Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02158052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*